Invesco
CTNM

Invesco’s Contineum Therapeutics CTNM Stock Holding History

Invesco’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Buy
+15,771
New +$207K ﹤0.01% 3491
2024
Q3 		– Sell
-10,771
Closed -$190K – 3907
2024
Q2 		$190K Buy
+10,771
New +$173K ﹤0.01% 3635

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Invesco's CTNM Position: Q2 2026 in Review

Invesco opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 15,771 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #3491 among its holdings. This is a return to the name: Invesco previously reported a position in CTNM as recently as Q2 2024.

Invesco first reported a position in CTNM in Q2 2024 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Invesco held 15,771 shares of Contineum Therapeutics worth $258K as of Q2 2026.
  • Contineum Therapeutics was a new Invesco position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3491 holding.
  • Invesco first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.